Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: hsg who wrote (388)	3/17/1999 1:46:00 AM
From: Robert Dydo	Read Replies (1) \| Respond to of 572

and may not be for long?

To: hsg who wrote (388)	3/23/1999 1:37:00 PM
From: Robert Dydo	Read Replies (2) \| Respond to of 572

Shares continue to be cheap, moreover XLX has become what had in the past driven the value down, a quarterly results appreciation mover. If the quarter will be good, it should go up while opposite is true. The speculative aspect, which propels early ventures is gone, partially due to silence on further developments of other instruments in the pipeline. I was hoping for releases in this regard or at least a summary of expectations with more detail what is going on and what is being planned. Any comments?